A Retrospective Cohort Study on Ventilator Associated Pneumonia Caused by Multi-Drug Resistance Organism in SQUH ICU
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Sultan Qaboos University
- Enrollment
- 319
- Locations
- 1
- Primary Endpoint
- Distribution of Multi-Drug Resistant (MDR) bacteria in VAP positive patients
Study Overview
Brief Summary
Ventilator-associated pneumonia (VAP) is an infection of the pulmonary parenchyma in patients exposed to invasive mechanical ventilation for at least 48 h and is part of ICU-acquired pneumonia. VAP is one of the most frequent ICU-acquired infections. Reported incidences vary widely from 5 to 40%, depending on the setting and diagnostic criteria. The estimated attributable mortality of VAP is around 10%. Investigators will focus this study on the current understanding of the epidemiology and treatment of VAP caused by multi-drug resistant (MDR) organisms. The MDR organisms are significant threats to the prognosis of the ICU patient. They are challenging to treat because of a limited number of newer antibiotics available for treatment. Understanding their distribution and sensitivity pattern may provide clues on how to deal with this significant problem. The current study examines the distribution of MDR organisms in VAP and its incidence and outcome. Investigators will also study the sensitivity pattern of these MDR organisms and how it affects the patient outcome. All patients admitted to adult ICU will be scanned, positive respiratory cultures will be noted, and those with VAP will be studied in detail. Patient data will be collected using the hospital information system.
Detailed Description
Introduction Ventilator-associated pneumonia (VAP) is defined as an infection of the pulmonary parenchyma in patients exposed to invasive mechanical ventilation for at least 48 h and is part of ICU-acquired pneumonia. VAP is one of the most frequent ICU-acquired infections. Reported incidences vary widely from 5 to 40%, depending on the setting and diagnostic criteria. VAP is associated with prolonged duration of mechanical ventilation and ICU stay. The estimated attributable mortality of VAP is around 10%.
Investigators will focus this study on the current understanding of the epidemiology and treatment of VAP caused by multi-drug resistant (MDR). Other conditions such as ventilator-associated tracheobronchitis are not detailed.
The MDR organisms are significant threats to the prognosis of the ICU patient. These organisms are usually acquired in hospitals due to multiple factors like antibiotic use, immunosuppression, prolonged stay in the hospital, etc. They are challenging to treat because of a limited number of newer antibiotics available for treatment. Understanding their distribution and sensitivity pattern may provide clues on how to deal with this significant problem.
Aim of the Study :
The current study examines the distribution of MDR organisms in VAP and its incidence and outcome.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Retrospective
Eligibility Criteria
- Ages
- 13 Years to — (Child, Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Adult patients (more than 13 years old) admitted to ICU (covid/non-covid) (for VAP rate)
- •Patient who got intubation and mechanical ventilation for more than 48 hours (for VAP0
- •Positive MDR bacterial respiratory culture for defining MDR VAP
- •Exclusion Criteria for MDR VAP:
- •Non-ventilated patients.
- •Patient with tracheobronchitis
- •Patients positive for fungal cultures
- •Patients with pneumonia before intubation
- •Non-MDR VAP
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Distribution of Multi-Drug Resistant (MDR) bacteria in VAP positive patients
Time Frame: upto 90 days
Frequency and classes of MDR organisms isolated from respiratory specimens of ventilated patients for more than 48 hours
Secondary Outcomes
- Outcome of MDR-VAP patients(upto 90 days)
- Incidence of MDR-VAP in ICU patients(upto 90 days)
- Antibiotic sensitivity for MDR-VAP causing organism(upto 90 days)
Investigators
Dr Jyoti Burad
Principle investigator
Sultan Qaboos University